Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
115 studies found for:    MAST CELL DISEASE
Show Display Options
Rank Status Study
21 Completed The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections
22 Completed Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
Condition: Mastocytosis
Intervention: Drug: masitinib (AB1010)
23 Completed Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myeloid Leukemia;   Polycythemia Vera;   Hypereosinophilic Syndrome;   Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)
24 Completed Stem Cell Transplantation to Treat Systemic Mastocytosis
Condition: Mastocytosis
Intervention: Procedure: Stem cell transplantation
25 Active, not recruiting
Has Results
Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Conditions: Systemic Mastocytosis, Aggressive (ASM);   Leukemia, Mast Cell;   Hematological Non-mast Cell Lineage Disease (AHNMD)
Intervention: Drug: Midostaurin
26 Not yet recruiting Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations
Conditions: Urticaria Pigmentosa;   Cutaneous Mastocytosis
Interventions: Other: skin biopsy;   Other: blood draw
27 Unknown  Use of Tamoxifen in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention:
28 Completed Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
Condition: Patients With Mastocytosis With Handicap and Bearing Mutations Asp-816-Val (D816V)
Intervention: Drug: masitinib
29 Unknown  Evaluation of Response of Dasatinib to Treat Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Dasatinib
30 Recruiting SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Conditions: Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Advanced Systemic Mastocytosis;   Advanced Symptomatic Primary Eosinophilic Disorder
Intervention: Drug: SL-401
31 Terminated Cromoglicate in Mastocytosis
Condition: Mastocytosis
Interventions: Drug: Cromoglicate;   Drug: Placebo
32 Completed Study on Mastocytosis for Rupatadine Treatment
Condition: Mastocytosis
Intervention: Drug: Rupatadin
33 Recruiting A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Condition: Indolent Systemic Mastocytosis
Intervention: Drug: AK002
34 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
35 Recruiting A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Conditions: Gastrointestinal Stromal Tumors;   Aggressive Systemic Mastocytosis;   Advanced Cancers
Intervention: Drug: DCC-2618
36 Recruiting Study of Mast Cell Precursors
Conditions: Normal Physiology;   Systemic Mastocytosis
Intervention:
37 Completed Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Conditions: Hypereosinophilic Syndrome;   Systemic Mastocytosis;   Chronic Myelomonocytic Leukemia;   Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
38 Completed Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Conditions: Non Neoplastic Condition;   Precancerous Condition
Intervention: Drug: thalidomide
39 Completed A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers
Conditions: Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive);   Hypereosinophilic Syndrome;   Systemic Mastocytosis
Intervention: Drug: Nilotinib
40 Active, not recruiting Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Condition: Leukemia
Intervention: Drug: Midostaurin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years